This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Peterson, E. Articles by Emlen, W. Search for Related Content PubMed PubMed Citation Articles by Peterson, E. Articles by Emlen, W. Social Bookmarking                         What's this?

Serum and urinary interleukin-6 in systemic lupus erythematosus

Division of Rheumatology, University of Iowa College of Medicine, Iowa City, Iowa

AD Robertson

Clinical Research Center, Department of Medicine, University of Colorado Health Sciences Center

W. Emlen

Division of Rheumatology, Department of Medicine, University of Colorado Health Sciences Center

Dysregulation of IL-6 production has been proposed as a pathogenic mechanism in SLE. We asked if serum or urine IL-6 levels could serve as indicators of systemic lupus erythematosus (SLE) disease activity. Using a sensitive enzyme-linked immunosorbent assay (ELISA), we measured serum and urine IL-6 in 56 SLE patients. Disease activity was assessed using a standard clinical index, the Systemic Lupus Activity Measure (SLAM). Only seven of 56 SLE patients had elevated serum IL-6 levels, compared with 1 of 32 controls (NS). SLE disease activity did not correlate with serum IL-6 levels. Sixteen of 50 SLE patients in whom urine IL-6 was measured exhibited elevated urine IL-6 levels, compared with 1 of 17 controls (p = < 0.05). Urine IL-6 levels correlated with overall disease activity and with the presence of active urinary sediment. Our results indicate that serum IL-6 is not a predictor of disease activity in SLE, but that urine IL-6 may be a marker of active nephritis.

Key Words: systemic lupus erythematosus • interleukin-6 • disease activity

Lupus, Vol. 5, No. 6, 571-575 (1996)
DOI: 10.1177/096120339600500603


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. R. Gilbert, D. G. Carnathan, P. C. Cogswell, L. Lin, A. S. Baldwin Jr, and B. J. Vilen Dendritic Cells from Lupus-Prone Mice Are Defective in Repressing Immunoglobulin Secretion J. Immunol., April 15, 2007; 178(8): 4803 - 4810. [Abstract] [Full Text] [PDF]

				S. A. Varghese, T. B. Powell, M. N. Budisavljevic, J. C. Oates, J. R. Raymond, J. S. Almeida, and J. M. Arthur Urine Biomarkers Predict the Cause of Glomerular Disease J. Am. Soc. Nephrol., March 1, 2007; 18(3): 913 - 922. [Abstract] [Full Text] [PDF]

				S. Yung, R. C.W. Tsang, Y. Sun, J. K.H. Leung, and T. M. Chan Effect of Human Anti-DNA Antibodies on Proximal Renal Tubular Epithelial Cell Cytokine Expression: Implications on Tubulointerstitial Inflammation in Lupus Nephritis J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3281 - 3294. [Abstract] [Full Text] [PDF]

				E Tackey, P E Lipsky, and G G Illei Rationale for interleukin-6 blockade in systemic lupus erythematosus Lupus, May 1, 2004; 13(5): 339 - 343. [Abstract] [PDF]

				L J Jara, O Vera-Lastra, J M Miranda, M Alcala, and J Alvarez-Nemegyci Prolactin in human systemic lupus erythematosus Lupus, October 1, 2001; 10(10): 748 - 756. [Abstract] [PDF]

				H. Schotte, B. Schluter, S. Rust, G. Assmann, W. Domschke, and M. Gaubitz Interleukin-6 promoter polymorphism (-174 G/C) in Caucasian German patients with systemic lupus erythematosus Rheumatology, April 1, 2001; 40(4): 393 - 400. [Abstract] [Full Text] [PDF]

				L. M VILÁ, J. R R. DEL RÍO, L. M VILÁ, Z. RÍOS, and E. RIVERA Lymphocyte populations and cytokine concentrations in pericardial fluid from a systemic lupus erythematosus patient with cardiac tamponade Ann Rheum Dis, November 1, 1999; 58(11): 720 - 721. [Full Text]